Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Natriuretic Peptides: early-phase trial registry
4 of 4 indexed Natriuretic Peptides trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 4 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Natriuretic Peptides: 4 US clinical trials tracked, 4 recruiting.
Natriuretic Peptides is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is University of Alabama at Birmingham, running 4 of these trials.
Enrollment posture brief
Registry condition natriuretic-peptides
OPEN 4 | RECR 100% | LATE 0 | EARLY 2 | RANK #4115 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Natriuretic Peptides lists 4 open slots (100% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Natriuretic Peptides on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Natriuretic Peptides is recruiting above its size-band peers.
4 of 4 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
CARBON: UAB Cardiovascular Research Biobank
University of Alabama at Birmingham
NCT05067231
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
University of Alabama at Birmingham
NCT04055428
GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study
University of Alabama at Birmingham
NCT05216042
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
University of Alabama at Birmingham
NCT04971720
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Natriuretic Peptides records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Natriuretic Peptides trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Natriuretic Peptides page
4 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Natriuretic Peptides trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Alabama at Birmingham sponsors the most Natriuretic Peptides trials on record, review their full trial history before evaluating a specific study. See University of Alabama at Birmingham's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Natriuretic Peptides condition card totals 4 registered trials; most-linked intervention Valsartan 80 mg Oral Tablet; top US site state Alabama. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.